Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 698542, 8 pages
Review Article

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab

1Medical Oncology 1 Unit, Venetian Oncology Institute-IRCCS, Via Gattamelata 64, 35128 Padua, Italy
2Neurosurgery Department, Padua Hospital, Padua, Italy
3Nuclear Medicine Service, Department of Diagnostic Medical Sciences, University of Padua, Padua, Italy

Received 12 February 2014; Accepted 3 March 2014; Published 31 March 2014

Academic Editor: Emeline Tabouret

Copyright © 2014 Giuseppe Lombardi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Fotemustine is a third-generation nitrosourea showing efficacy in various types of tumors such as melanoma and glioma. We reviewed the most important studies on fotemustine treatment in glioma patients analyzing its pharmacological profile and its activity and safety. Fotemustine was used as single agent or in association with new targeted drugs such as bevacizumab; fotemustine was used both as first-line chemotherapy before temozolomide era and in refractory-temozolomide patients during temozolomide era. Finally, analyzing and comparing the activity and safety of fotemustine alone or in combination with bevacizumab versus other nitrosoureas such as lomustine, we may suggest that the combination treatment with bevacizumab and fotemustine may be active and tolerable in patients with high grade gliomas.